Company intelligence / Profile preview

葆棠华

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Baotanghua (Beijing) Pharmaceutical Technology is a clinical-stage biotechnology company focused on the development of innovative small molecule drugs for metabolic diseases. The company's primary focus is on treating gout and hyperuricemia, with its lead candidate BTH-1514 currently undergoing Phase 2 clinical trials. BTH-1514 is designed as a highly selective URAT1 inhibitor to provide a safer and more effective alternative to existing urate-lowering therapies. Baotanghua leverages its internal research and development platform to advance a pipeline of candidates targeting chronic metabolic conditions.

Therapeutic areas: RheumatologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 葆棠华.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 葆棠华.

Explore the full profile